Radiographically, zirconia implants revealed statistically significantly less crestal peri-implant bone loss compared to titanium implants at the end of the active progression period (Ti-SLA: 3.92 mm; ZrO<sub>2</sub>-ZLA: 2.65 mm; P < .01); however, no significant differences occurred after the spontaneous progression period (P = .6).
The relationship between negative acts and pain intensity was significantly stronger for subjects with the LALA genotype than for subjects with the SLA/LALG/SLG genotype.
The aim of this study was to prospectively evaluate the clinical outcome as well as the postoperative course of pain after arthroscopic type II SLAP repair.
We obtained δ<sup>2</sup> H values (normalized on the VSMOW-SLAP scale) from both glassy-carbon-packed (GP) and chromium-packed (Cr) reactor configurations from bone collagen (n = 231) from a variety of archaeological sites, using a High-Temperature Conversion Elemental Analyzer (TC/EA) coupled to a Delta Plus XP isotope ratio mass spectrometer.
Herein, we have evaluated the immunostimulatory effects of SLA archaeosomes when used as adjuvant with ovalbumin (OVA) and hepatitis B surface antigen (HBsAg) and compared this to various other adjuvants including TLR3/4/9 agonists, oil-in-water and water-in-oil emulsions and aluminum hydroxide.
However, using the rA2 protein or L. braziliensisSLA as controls, significant cross-reactivity was found when these samples were used, hampering their sensitivity and specificity values for the diagnosis.
Molecular characterization and evaluation of Onchocerca volvulus-secreted larval acidic protein 1 (SLAP1) as a putative vaccine candidate on endemic population of lymphatic filariasis.
In the present study, stage-specific expression of secreted larval acidic protein 1 (SLAP1) was identified; an ALT orthologue from Onchocerca volvulus was cloned, expressed, and purified as a recombinant protein.
Over-expression and knock-down experiments in ALL in vitro model revealed that transgenic SLA alone had no effect on survival or cell cycle progression, nor did it affect sensitivity to, or kinetics of, GC-induced apoptosis.
Over-expression and knock-down experiments in ALL in vitro model revealed that transgenic SLA alone had no effect on survival or cell cycle progression, nor did it affect sensitivity to, or kinetics of, GC-induced apoptosis.
Over-expression and knock-down experiments in ALL in vitro model revealed that transgenic SLA alone had no effect on survival or cell cycle progression, nor did it affect sensitivity to, or kinetics of, GC-induced apoptosis.